Compare Stocks: SUPN, RDY, CRNX, and LNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$84.95	$78.89	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
LNTH Lantheus	$100.97 0.0%	$103.12	$49.67 ▼ $111.86	$6.59B	-0.03	1.46 million shs	859,895 shs
RDY Dr. Reddy's Laboratories	$11.97 -0.5%	$12.60	$11.36 ▼ $15.67	$9.99B	0.28	2.47 million shs	2.34 million shs
SUPN Supernus Pharmaceuticals	$43.53 -1.0%	$46.69	$42.45 ▼ $59.68	$2.53B	0.56	584,861 shs	444,196 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	0.00%	+0.13%	+1.23%	+158.05%	+145.17%
LNTH Lantheus	0.00%	+0.20%	-0.10%	-0.01%	+83.08%
RDY Dr. Reddy's Laboratories	0.00%	-1.64%	-1.28%	-9.76%	-15.62%
SUPN Supernus Pharmaceuticals	0.00%	-0.46%	-6.91%	-2.73%	-3.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$84.95	$78.89	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
LNTH Lantheus	$100.97 0.0%	$103.12	$49.67 ▼ $111.86	$6.59B	-0.03	1.46 million shs	859,895 shs
RDY Dr. Reddy's Laboratories	$11.97 -0.5%	$12.60	$11.36 ▼ $15.67	$9.99B	0.28	2.47 million shs	2.34 million shs
SUPN Supernus Pharmaceuticals	$43.53 -1.0%	$46.69	$42.45 ▼ $59.68	$2.53B	0.56	584,861 shs	444,196 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	0.00%	+0.13%	+1.23%	+158.05%	+145.17%
LNTH Lantheus	0.00%	+0.20%	-0.10%	-0.01%	+83.08%
RDY Dr. Reddy's Laboratories	0.00%	-1.64%	-1.28%	-9.76%	-15.62%
SUPN Supernus Pharmaceuticals	0.00%	-0.46%	-6.91%	-2.73%	-3.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.65% Downside
LNTH Lantheus	2.29	Hold	$108.11	7.07% Upside
RDY Dr. Reddy's Laboratories	1.50	Reduce	N/A	N/A
SUPN Supernus Pharmaceuticals	2.71	Moderate Buy	$62.83	44.34% Upside

Current Analyst Ratings Breakdown

Latest SUPN, RDY, CRNX, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	CRNX Crinetics Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/6/2026	SUPN Supernus Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
8/3/2026	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$125.00 ➝ $102.50
8/3/2026	LNTH Lantheus	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$110.00 ➝ $102.50
8/3/2026	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$102.50
8/3/2026	LNTH Lantheus	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$102.50
8/3/2026	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
LNTH Lantheus	$1.54B	4.27	$6.39 per share	15.81	$20.10 per share	5.02
RDY Dr. Reddy's Laboratories	$331.19B	0.03	$0.85 per share	14.13	$4.90 per share	2.44
SUPN Supernus Pharmaceuticals	$718.95M	3.52	$3.78 per share	11.53	$17.74 per share	2.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.39	18.49	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.44	27.21	21.00	2.51	10.15%	9.49%	6.32%	10/23/2026 (Estimated)
SUPN Supernus Pharmaceuticals	-$38.55M	-$1.92	N/A	11.28	0.80	-13.23%	11.13%	8.10%	11/3/2026 (Estimated)

Latest SUPN, RDY, CRNX, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.50%	+6.96%	13.64%	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
LNTH Lantheus	0.43	3.06	2.89
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
LNTH Lantheus	99.06%
RDY Dr. Reddy's Laboratories	3.85%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	3.80%
LNTH Lantheus	1.70%
RDY Dr. Reddy's Laboratories	2.00%
SUPN Supernus Pharmaceuticals	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.06 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.97 million	Optionable
SUPN Supernus Pharmaceuticals	580	58.13 million	53.19 million	Optionable

SUPN, RDY, CRNX, and LNTH Headlines

Recent News About These Companies

Jupiter Topco LLC Buys Shares of 23,254 Supernus Pharmaceuticals, Inc. $SUPN

September 6 at 4:39 AM | marketbeat.com

The Manufacturers Life Insurance Company Invests $1.30 Million in Supernus Pharmaceuticals, Inc. $SUPN

September 5 at 4:39 AM | marketbeat.com

Legal & General Group Plc Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

September 3 at 4:40 AM | marketbeat.com

Supernus Pharmaceuticals to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

Bank of New York Mellon Corp Makes New $17.55 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

September 1, 2026 | marketbeat.com

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

August 31, 2026 | globenewswire.com

156,422 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Man Group plc

August 30, 2026 | marketbeat.com

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

Freestone Grove Partners LP Invests $14.72 Million in Supernus Pharmaceuticals, Inc. $SUPN

August 28, 2026 | marketbeat.com

91,070 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by Algert Global LLC

August 28, 2026 | marketbeat.com

25,858 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by PDT Partners LLC

August 27, 2026 | marketbeat.com

Deutsche Bank AG Takes $2.96 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

August 27, 2026 | marketbeat.com

Elmind Capital LP Invests $3.26 Billion in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

BlackRock Inc. Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New $1.29 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

August 26, 2026 | marketbeat.com

Quantbot Technologies LP Purchases Shares of 47,700 Supernus Pharmaceuticals, Inc. $SUPN

August 25, 2026 | marketbeat.com

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

August 24, 2026 | zacks.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Supernus Pharmaceuticals Inc

August 22, 2026 | money.usnews.com

NFJ Investment Group LLC Makes New $2.46 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

August 22, 2026 | marketbeat.com

Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN

August 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, RDY, CRNX, and LNTH Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)

As of 09/1/2026

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Lantheus NASDAQ:LNTH

$100.97 -0.01 (-0.01%)

As of 09/4/2026 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Dr. Reddy's Laboratories NYSE:RDY

$11.97 -0.06 (-0.50%)

As of 09/4/2026 03:58 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Supernus Pharmaceuticals NASDAQ:SUPN

$43.53 -0.44 (-1.00%)

As of 09/4/2026 04:00 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SUPN, RDY, CRNX, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SUPN, RDY, CRNX, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SUPN, RDY, CRNX, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, RDY, CRNX, and LNTH Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

Lantheus NASDAQ:LNTH

Dr. Reddy's Laboratories NYSE:RDY

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SUPN, RDY, CRNX, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SUPN, RDY, CRNX, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SUPN, RDY, CRNX, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, RDY, CRNX, and LNTH Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

Lantheus NASDAQ:LNTH

Dr. Reddy's Laboratories NYSE:RDY

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools